Hyperlipidemia
-
Evaluation
-
General—a significant contributor to atherosclerosis and consequently coronary heart disease (CHD)
-
Low-density lipoprotein (LDL) is a primary mediator of atherosclerosis.
-
-
Epidemiology—CHD accounts for 500,000 deaths per year in the United States (no.1 cause of morbidity and mortality)
-
Risk factors impacting LDL goals
-
Age (men of age 45 years or older, women of age 55 years or older)
-
Smoking
-
Hypertension (blood pressure [BP] ” class=LK href=”javascript:void(0)” target=right xpath=”/CT{06b9ee1beed59419a81e5e1e1a4f60b0cc8cd1057525de73425b2b43f4df7f1b75d2129a25d01f3042ff2fa0b188b440}/ID(AB1-M10)”>>140/90 or patient is taking antihypertensives)
-
Family history of premature CHD (first degree male younger than 55 years, first degree female younger than 65 years)
-
-
CHD risk equivalents
-
Diabetes
-
-
Risk stratification and assessment (see Table 2.35.1)
-
-
Treatment—may try therapeutic lifestyle changes (TLC) for 12 weeks before considering medications.
-
TLC
-
Diet—low in saturated fat and trans fatty acids; cholesterol <A onclick="get_content(event,'AB1-M12'); return false;" onmouseover="window.status=this.title; return true;" onmouseout="window.status=''; return true;" title="<200 mg per day
-
Weight loss—decreases LDL and improves insulin sensitivity
-
No smoking—increases HDL
-
-
Medications (initially check lipid profile and liver function tests (LFTs) every 6 weeks, then q6mo to every 12 months when LDL is normal)
-
-
Note: Watch for myalgias and rhabdomyolysis with statins.
-
Stay updated, free articles. Join our Telegram channel
-
-

Full access? Get Clinical Tree

